The role of complement in the pathogenesis of experimental allergic encephalomyelitis - PubMed (original) (raw)
. 1989 Aug:112 ( Pt 4):895-911.
doi: 10.1093/brain/112.4.895.
Affiliations
- PMID: 2476195
- DOI: 10.1093/brain/112.4.895
The role of complement in the pathogenesis of experimental allergic encephalomyelitis
C Linington et al. Brain. 1989 Aug.
Abstract
The role of complement in the pathogenesis of demyelination and inflammation has been investigated in a synergistic model of acute experimental allergic encephalomyelitis (EAE) in the Lewis rat. Depletion of serum complement with cobra venom factor (CVF) suppressed the clinical expression of acute inflammatory EAE induced either by immunization with 50 micrograms guinea pig basic protein (MBP) in Freund's complete adjuvant, or by the passive transfer of 10(7), but not 5 X 10(7) MBP activated spleen cells. Despite the suppression of clinical disease in actively induced EAE, treatment with CFF only had a significant effect on the severity of CNS inflammation in early disease (12 days postimmunization) when the number of inflammatory foci was reduced by 35%. Three days later this difference had resolved and no significant difference could be detected in the severity of CNS inflammation, although control animals exhibited severe disease, the CVF treated group being clinically normal. Demyelination in these models is initiated by systemic injection of the antimyelin oligodendrocyte glycoprotein (MOG) monoclonal antibody, 8-18C5, which in vitro lyses oligodendrocytes in a dose, Fc and complement-dependent manner and in vivo induces extensive CNS demyelination in rats with EAE. Treatment with CVF reduced the ability of this antibody to initiate demyelination in vivo and furthermore, its F(ab)2' fragment had no effect on the clinical course of EAE and was unable to initiate demyelination in normal animals. Complement-dependent mechanisms are therefore involved both in the clinical expression of acute inflammatory lesions and in the pathogenesis of antibody-mediated demyelination in EAE.
Similar articles
- Antibody-mediated demyelination in experimental allergic encephalomyelitis is independent of complement membrane attack complex formation.
Piddlesden S, Lassmann H, Laffafian I, Morgan BP, Linington C. Piddlesden S, et al. Clin Exp Immunol. 1991 Feb;83(2):245-50. doi: 10.1111/j.1365-2249.1991.tb05622.x. Clin Exp Immunol. 1991. PMID: 1993358 Free PMC article. - The complement system contributes to the pathology of experimental autoimmune encephalomyelitis by triggering demyelination and modifying the antigen-specific T and B cell response.
Hundgeburth LC, Wunsch M, Rovituso D, Recks MS, Addicks K, Lehmann PV, Kuerten S. Hundgeburth LC, et al. Clin Immunol. 2013 Mar;146(3):155-64. doi: 10.1016/j.clim.2012.12.007. Epub 2012 Dec 22. Clin Immunol. 2013. PMID: 23352967 - Demyelinating experimental allergic encephalomyelitis (EAE) in the rat: treatment with a monoclonal antibody against activated T cells.
Schluesener HJ, Sobel RA, Weiner HL. Schluesener HJ, et al. J Neuroimmunol. 1988 Jul;18(4):341-51. doi: 10.1016/0165-5728(88)90055-0. J Neuroimmunol. 1988. PMID: 2454946 - Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.
Tegla CA, Cudrici C, Rus V, Ito T, Vlaicu S, Singh A, Rus H. Tegla CA, et al. J Neuroimmunol. 2009 Aug 18;213(1-2):3-11. doi: 10.1016/j.jneuroim.2009.06.006. Epub 2009 Jul 4. J Neuroimmunol. 2009. PMID: 19577811 Free PMC article. Review. - TNF-alpha receptor fusion protein prevents experimental auto-immune encephalomyelitis and demyelination in Lewis rats: an overview.
Klinkert WE, Kojima K, Lesslauer W, Rinner W, Lassmann H, Wekerle H. Klinkert WE, et al. J Neuroimmunol. 1997 Feb;72(2):163-8. doi: 10.1016/s0165-5728(96)00183-x. J Neuroimmunol. 1997. PMID: 9042109 Review.
Cited by
- Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with a neurotropic coronavirus.
Kim TS, Perlman S. Kim TS, et al. Am J Pathol. 2005 Mar;166(3):801-9. doi: 10.1016/S0002-9440(10)62301-2. Am J Pathol. 2005. PMID: 15743792 Free PMC article. - IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis.
Benkhoucha M, Molnarfi N, Santiago-Raber ML, Weber MS, Merkler D, Collin M, Lalive PH. Benkhoucha M, et al. J Neuroinflammation. 2012 Sep 3;9:209. doi: 10.1186/1742-2094-9-209. J Neuroinflammation. 2012. PMID: 22943418 Free PMC article. - Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.
Peschl P, Schanda K, Zeka B, Given K, Böhm D, Ruprecht K, Saiz A, Lutterotti A, Rostásy K, Höftberger R, Berger T, Macklin W, Lassmann H, Bradl M, Bennett JL, Reindl M. Peschl P, et al. J Neuroinflammation. 2017 Oct 25;14(1):208. doi: 10.1186/s12974-017-0984-5. J Neuroinflammation. 2017. PMID: 29070051 Free PMC article. - Anti-macrophage CR3 antibody blocks myelin phagocytosis by macrophages in vitro.
Brück W, Friede RL. Brück W, et al. Acta Neuropathol. 1990;80(4):415-8. doi: 10.1007/BF00307696. Acta Neuropathol. 1990. PMID: 2239153 - Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis.
Weerth SH, Rus H, Shin ML, Raine CS. Weerth SH, et al. Am J Pathol. 2003 Sep;163(3):1069-80. doi: 10.1016/S0002-9440(10)63466-9. Am J Pathol. 2003. PMID: 12937147 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous